Literature DB >> 7214522

Aortic cusp involvement causing severe aortic regurgitation in a case of relapsing polychondritis.

G S Sohi, A M Desai, W W Ward, N C Flowers.   

Abstract

A case with relapsing polychondritis is described where primary involvement of the aortic valve cusps produced severe aortic regurgitation requiring valve replacement. An aneurysmal dilatation of the ascending aorta developing later led to disruption of the prosthesis requiring re-operation. Superior vena caval obstruction, an abdominal aortic aneurysm which ruptured and required resection, and obstructive lesions in common iliac arteries, presumably the result of the same process that involved the aorta and the cartilaginous structures, were also seen.

Entities:  

Mesh:

Year:  1981        PMID: 7214522     DOI: 10.1002/ccd.1810070111

Source DB:  PubMed          Journal:  Cathet Cardiovasc Diagn        ISSN: 0098-6569


  5 in total

Review 1.  Aortic involvement in relapsing polychondritis: case-based review.

Authors:  Mustafa Erdogan; Sinem Nihal Esatoglu; Gulen Hatemi; Vedat Hamuryudan
Journal:  Rheumatol Int       Date:  2019-11-25       Impact factor: 2.631

2.  Relapsing polychondritis: bone marrow and circular fibrous nodules in the aorta.

Authors:  G E Wilson; P S Hasleton; J J Manns; J S Marks
Journal:  Ann Rheum Dis       Date:  1990-10       Impact factor: 19.103

3.  Early aortic valve cusp rupture in relapsing polychondritis.

Authors:  D A Marshall; R Jackson; A P Rae; H A Capell
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

4.  Relapsing polychondritis with severe aortic insufficiency.

Authors:  R Manna; V Annese; G Ghirlanda; F Pennestri; A V Greco; M A Pala; G B Bochicchio; M Magaro
Journal:  Clin Rheumatol       Date:  1985-12       Impact factor: 2.980

5.  Patient Perception of Disease-Related Symptoms and Complications in Relapsing Polychondritis.

Authors:  Marcela A Ferrada; Peter C Grayson; Shubhasree Banerjee; Keith A Sikora; Robert A Colbert; Ninet Sinaii; James D Katz
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-07-04       Impact factor: 4.794

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.